KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Net Cash Flow (2016 - 2025)

Boston Scientific's Net Cash Flow history spans 17 years, with the latest figure at $668.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 132.84% year-over-year to $668.0 million; the TTM value through Dec 2025 reached $1.5 billion, up 442.24%, while the annual FY2025 figure was $1.5 billion, 442.24% up from the prior year.
  • Net Cash Flow for Q4 2025 was $668.0 million at Boston Scientific, down from $737.0 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.4 billion in Q1 2024 and bottomed at -$2.0 billion in Q4 2024.
  • The 5-year median for Net Cash Flow is $27.5 million (2021), against an average of $7.0 million.
  • The largest annual shift saw Net Cash Flow skyrocketed 6844.44% in 2022 before it crashed 2411.11% in 2024.
  • A 5-year view of Net Cash Flow shows it stood at $9.0 million in 2021, then surged by 6844.44% to $625.0 million in 2022, then crashed by 112.96% to -$81.0 million in 2023, then plummeted by 2411.11% to -$2.0 billion in 2024, then soared by 132.84% to $668.0 million in 2025.
  • Per Business Quant, the three most recent readings for BSX's Net Cash Flow are $668.0 million (Q4 2025), $737.0 million (Q3 2025), and -$180.0 million (Q2 2025).